Icrucumab
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors[1].
Product Specifications
CAS Number
1024603-92-6
Product Name Alternative
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/icrucumab.html
Purity
99.99
Solubility
10 mM in DMSO
Smiles
[Icrucumab]
Molecular Weight
(146.68 kDa)
References & Citations
[1]LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32 (2) :303-11.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC882156-500 1x 500 µL
Catenin, gamma (Cardiomyocyte Marker) (rCTNG/1664), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNUB3308-500 1x 500 µL
Napsin A (Lung Adenocarcinoma Marker) (NAPSA/3308), 0.2mg/mL
Sign In for Pricing
View Details 
